[SCHEDULE 13D/A] Xtant Medical Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Form 4 shows KLA Corp. (KLAC) EVP & CFO Bren D. Higgins settling tax withholdings triggered by scheduled RSU vesting, not an open-market trade. Two Code “F” transactions were reported:

• 08/03/25: 722.381 shares withheld at $886.64 after 25 % of a 5,828-unit 2023 RSU grant vested.
• 08/04/25: 738.743 shares withheld at the same price following 25 % vesting of a 5,961-unit 2022 RSU grant.

Post-withholding, Higgins directly owns 23,182.006 KLAC shares, including 13,213.912 unvested RSUs. Because Code “F” indicates share retention for taxes, the filing is routine and signals no directional change in insider sentiment or corporate outlook.

Insights

Securities Analyst

TL;DR: Routine tax-withholding; no bullish or bearish signal.

These Code “F” dispositions reflect automatic share surrender to cover taxes on vested RSUs. Higgins retains a sizable holding (≈ 23 k shares), so equity exposure remains intact. No open-market selling or buying occurred, limiting market relevance. Neutral for valuation or sentiment models.

Corporate Governance Expert

TL;DR: Standard Section 16 compliance; administrative.

The filing complies with Section 16(a) and Rule 10b5-1(c) disclosure standards. Transactions are plan-based, avoiding potential optics of opportunistic trading. No governance red flags emerge.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Xtant Medical Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.000001 per share

(Title of Class of Securities)

98420P308

(CUSIP Number)

Taki Vasilakis
130 Main St., 2nd Floor,
New Canaan, CT, 06840
203-308-4440

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/01/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 98420P308

1

Name of reporting person

Nantahala Capital Partners Limited Partnership

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 16,380,396.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 16,380,396.00

11

Aggregate amount beneficially owned by each reporting person

16,380,396.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

11.8 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 98420P308

1

Name of reporting person

Nantahala Capital Management, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 68,394,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 68,394,000.00

11

Aggregate amount beneficially owned by each reporting person

68,394,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

49.1 %

14

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13D

CUSIP No. 98420P308

1

Name of reporting person

Harkey Wilmot B.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 68,394,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 68,394,000.00

11

Aggregate amount beneficially owned by each reporting person

68,394,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

49.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 98420P308

1

Name of reporting person

Mack Daniel

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 68,394,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 68,394,000.00

11

Aggregate amount beneficially owned by each reporting person

68,394,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

49.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.000001 per share
(b)	Name of Issuer: Xtant Medical Holdings, Inc.
(c)	Address of Issuer's Principal Executive Offices: 664 Cruiser Lane, Belgrade, MONTANA , 59714.
Item 1 Comment: This Amendment No. 1 ("Amendment No. 1") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on behalf of Nantahala Capital Partners Limited Partnership, a Massachusetts limited liability partnership ("NCP"), Nantahala Capital Management, LLC, a Massachusetts limited liability company ("Nantahala"), and Messrs. Wilmot B. Harkey and Daniel Mack, the principals of Nantahala (collectively, the "Reporting Persons") on April 17, 2025 (the "Original Schedule 13D"), relating to Common Stock, par value $0.000001 per share (the "Common Stock"), of Xtant Medical Holdings, Inc. a Delaware corporation (the "Issuer"). Capitalized terms used but not defined in this Amendment have the meanings set forth in the Original Schedule 13D. Except as specifically provided herein, this Amendment does not modify any of the information reported in the Original Schedule 13D. This Schedule 13D relates to Common Stock of the Issuer purchased by Nantahala through the accounts of certain private funds, including NCP, and managed accounts (collectively, the "Nantahala Investors"). Nantahala serves as the investment adviser to the Nantahala Investors and may direct the vote and dispose of the shares of Common Stock held by the Nantahala Investors. As the principals of Nantahala, Mr. Harkey and Mr. Mack may direct the vote and disposition of the shares of Common Stock held by the Nantahala Investors.
Item 4.	Purpose of Transaction
	Item 4 is amended by the addition of the following: On August 1, 2025, the Board of Directors (the "Board") of the Issuer elected Abhinav (Abi) Jain, an Analyst at NCM, to the Board. Mr. Jain was appointed to serve as a member of the Compensation Committee and Nominating and Corporate Governance Committee of the Board. Mr. Jain's appointment was described further by the Issuer in a Form 8-K filed with the SEC on August 4, 2025.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is amended and restated as follows: See Items 11 and 13 of the cover pages. The percentage of the outstanding shares of Common Stock beneficially owned by the Reporting Persons reported herein is based on 139,323,172 shares of Common Stock outstanding, as reported by the Issuer in a Final Prospectus filed with the SEC on May 20, 2025 pursuant to Rule 424(b)(3).
(b)	Item 5(b) is amended and restated as follows: See Items 7, 8, 9 and 10 of the cover pages.
(c)	Item 5(c) is amended by the addition of the following: Other than the transactions reported herein, if applicable, no Reporting Person or Other Officer has effected any transactions in the Common Stock of the Issuer in the prior sixty days.
(d)	Item 5(d) is amended and restated as follows: The Nantahala Investors hold the shares of Common Stock reported herein, including more than 5% of the outstanding shares of Common Stock beneficially owned by the Reporting Persons but held by Blackwell Partners LLC - Series A and Pinehurst Partners, L.P. No person other than the Nantahala Investors is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 is amended by the addition of the following: The disclosure set forth in Item 4 to this Amendment No. 1 is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nantahala Capital Partners Limited Partnership

Signature:	/s/ Taki Vasilakis
Name/Title:	Taki Vasilakis, Chief Compliance Officer
Date:	08/05/2025

Nantahala Capital Management, LLC

Signature:	/s/ Taki Vasilakis
Name/Title:	Taki Vasilakis, Chief Compliance Officer
Date:	08/05/2025

Harkey Wilmot B.

Signature:	/s/ Wilmot B. Harkey
Name/Title:	Wilmot B. Harkey
Date:	08/05/2025

Mack Daniel

Signature:	/s/ Daniel Mack
Name/Title:	Daniel Mack
Date:	08/05/2025

FAQ

How many KLA (KLAC) shares did CFO Bren Higgins dispose of?

A total of 1,461.124 shares were withheld for taxes across two vesting events.

What price was used for the tax-withholding transactions?

Both withholdings were calculated at the $886.64 closing price on 08/01/25.

How many KLAC shares does the CFO now own?

Higgins now directly owns 23,182.006 shares, including unvested RSUs.

What does transaction code “F” mean on Form 4 filings?

Code “F” indicates shares were withheld by the issuer solely to pay taxes due on equity-award vesting.

Is this insider activity considered a sell signal for KLAC stock?

No; the shares were surrendered for tax purposes and do not reflect discretionary selling.